Trilaciclib is a cyclin-dependent kinase (CDK) 4/6 inhibitor indicated as a myeloprotective agent to reduce the severity of chemotherapy-induced bone marrow suppression. By transiently arresting hematopoietic… Read more

![Chemical structure of N-(5-(4-Methylpiperazin-1-yl)pyridin-2-yl)-N-(6'-oxo-7',8'-dihydro-6'H-spiro[cyclohexane-1,9'-pyrazino[1',2':1,5]pyrrolo[2,3-d]pyrimidin]-2'-yl)nitrous Amide](/_next/image?url=https%3A%2F%2Fassets.splendidlab.com%2FN-5-4-Methylpiperazin-1-ylpyridin-2-yl-N-6-oxo-78-dihydro-6H-spirocyclohexane-19-pyrazino1215pyrrolo23-dpyrimidin-2-ylnitrous-Amide.png&w=3840&q=75)





















Trilaciclib is a cyclin-dependent kinase (CDK) 4/6 inhibitor indicated as a myeloprotective agent to reduce the severity of chemotherapy-induced bone marrow suppression. By transiently arresting hematopoietic stem and progenitor cells in the cell cycle, this medication helps protect bone marrow from cytotoxic damage. To support rigorous quality control and method development, this category provides a comprehensive range of reference standards, including the active pharmaceutical ingredient, synthesis-related impurities, and metabolic derivatives. Pharmaceutical laboratories rely on these materials, such as specific N-desmethyl and nitroso derivatives, to perform accurate impurity profiling and detect potential contaminants. Additionally, stable isotope labelled Trilaciclib compounds serve as essential internal standards for reliable quantification during complex analytical procedures. Together, these high-purity materials are vital for conducting robust method validation and ensuring the safety and quality of the drug product throughout the development process.